Advertisement
U.S. markets open in 2 hours 6 minutes
  • S&P Futures

    5,305.75
    -2.50 (-0.05%)
     
  • Dow Futures

    40,138.00
    -6.00 (-0.01%)
     
  • Nasdaq Futures

    18,492.50
    -11.25 (-0.06%)
     
  • Russell 2000 Futures

    2,138.60
    +0.20 (+0.01%)
     
  • Crude Oil

    82.41
    +1.06 (+1.30%)
     
  • Gold

    2,232.40
    +19.70 (+0.89%)
     
  • Silver

    24.75
    +0.00 (+0.01%)
     
  • EUR/USD

    1.0797
    -0.0033 (-0.30%)
     
  • 10-Yr Bond

    4.1960
    0.0000 (0.00%)
     
  • Vix

    12.98
    +0.20 (+1.56%)
     
  • GBP/USD

    1.2625
    -0.0013 (-0.10%)
     
  • USD/JPY

    151.3480
    +0.1020 (+0.07%)
     
  • Bitcoin USD

    70,829.95
    +745.47 (+1.06%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,955.99
    +24.01 (+0.30%)
     
  • Nikkei 225

    40,168.07
    -594.66 (-1.46%)
     

U.S. FDA panel: data support safety, efficacy of Merck allergy drug

Jan 28 (Reuters) - Merck & Co's experimental allergy drug, Ragwitek, appears safe and effective for use in patients between the ages of 18 and 65, a panel of advisors to the U.S. Food and Drug Administration concluded on Tuesday.

The panel voted 6 to 2, with one abstention, that data supported the drug's efficacy. It voted 8 to 0, with one abstention, that it supported the drug's safety.

Ragwitek is designed to treat allergic reaction to short ragweed pollen.

Advertisement